XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer
October 28, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2...
XOMA Earns $1.9 Million Associated with Two Partner Developments
October 14, 2020 07:30 ET
|
XOMA Corporation
Rezolute’s recent private placement triggers $1.4 million payment to XOMAIn an unrelated development, a partner initiated Phase 2 development of an undisclosed asset, which triggers $0.5 million...
XOMA to Present at Upcoming Investor Conferences
September 02, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: ...
XOMA Reports Second Quarter 2020 Financial Results
August 06, 2020 16:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), today announced its second quarter 2020 royalty asset portfolio advancements and financial results. “With a...
XOMA to Present at the 2020 Wedbush PacGrow Healthcare Conference
August 05, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present a Company business update at the Wedbush...
XOMA Announces Natasha Hernday Joins its Board of Directors
July 01, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, Inc., has...
XOMA Added to the Russell 2000® and Russell 3000® Indexes
June 29, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the annual...
XOMA Reports First Quarter 2020 Financial Results and Provides COVID-19 Business Update
May 05, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) reported its first quarter 2020 financial results and provided a COVID-19 business update. “Our first priority...
XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights
March 10, 2020 07:30 ET
|
XOMA Corporation
Added more than 20 new partner-funded programs in 2019 with potential for milestone and royalty payments Received $15.8 million from partners during the year Current cash balance sufficient to fund...
Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement
March 09, 2020 05:00 ET
|
XOMA Corporation
AHMEDABAD, India and EMERYVILLE, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation (Nasdaq: XOMA) today announced they...